| Ytd | 67.74% | |
| 1y | 564.96% |
| Open | 2.65 | Prev Close | 2.63 | Low | 2.52 | High | 2.66 | Mkt Cap | 93.42M |
| Vol | 120.03K | Avg Vol | 802.58K | EPS | -0.32 | P/E | -8.22 | Forward P/E | -0.47 |
| Beta | 1.77 | Short Ratio | 0.53 | Inst. Own | 20.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.70 | 200-d Avg | 1.82 | 1yr Est | 3.33 |
EQ News
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweigh
Three-year renewal follows early campaign results that delivered up to 40% increases in average orde
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology in
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammator
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected appro
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup wit
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Aberdeen Group plc grew its holdings in Equillium, Inc. (NASDAQ: EQ) by 523.6% in the undefined quar
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected app
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Equillium, Inc. (NASDAQ: EQ - Get Free Report) COO Christine Zedelmayer sold 120,312 shares of the s
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceed
Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial init
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology in
Equillium, Inc. (NASDAQ: EQ - Get Free Report) was the target of a large growth in short interest du
Monday saw 196 companies set new 52-week lows.
On Wednesday, 329 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Stocks Which Set New 52-Week Low Yesterday, October 23rd